Literature DB >> 9364014

Studies of chemopreventive effects of budenoside on benzo[a]pyrene-induced neoplasia of the lung of female A/J mice.

L W Wattenberg1, R D Estensen.   

Abstract

The objective of the present investigation was to determine conditions under which the synthetic glucocorticoid, budenoside, will inhibit benzo[a]pyrene (BaP)-induced pulmonary carcinogenesis when administered in the post-initiation period. For this purpose, female A/J mice were employed. The animals were given three administrations of 2 mg of BaP by oral intubation during a 1-week period. Budenoside was fed in the diet subsequent to the last dose of BaP. Using this format, two experiments were carried out to determine the effects of varying the time of administration of budenoside on the magnitude of the inhibition obtained. In both experiments, one group of mice was fed budenoside (1.5 mg/kg of diet) from 1 week after the last dose of BaP until the termination of the experiment, 15 weeks later. The reduction of pulmonary tumor formation under these conditions was 89% in the first experiment and 78% in the second (average 84%). In the first experiment the effects of feeding budenoside only during weeks 1-5 after BaP administration was studied. Under these conditions, inhibition of pulmonary tumor formation was 35%. In the second experiment, the effects of postponing the start of feeding budenoside was determined. In mice in which the budenoside feeding was delayed until 5 weeks after the last dose of BaP and then continued for the duration of the protocol, a 67% inhibition of tumor formation was found. The data obtained indicate that budenoside will produce inhibition of pulmonary adenoma formation when fed either early or late in the post-initiation stage of carcinogenesis, and that feeding throughout the entire post-initiation period gives maximum inhibition.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9364014     DOI: 10.1093/carcin/18.10.2015

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

1.  Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice.

Authors:  Huijing Fu; Jingjie Zhang; Jing Pan; Qi Zhang; Yan Lu; Weidong Wen; Ronald A Lubet; Eva Szabo; Ruth Chen; Yian Wang; Da-Ren Chen; Ming You
Journal:  Mol Carcinog       Date:  2011-03-03       Impact factor: 4.784

2.  Influence of FHIT on benzo[a]pyrene-induced tumors and alopecia in mice: chemoprevention by budesonide and N-acetylcysteine.

Authors:  Roumen Balansky; Francesco D'Agostini; Gancho Ganchev; Alberto Izzotti; Barbara Di Marco; Ronald A Lubet; Nicola Zanesi; Carlo M Croce; Silvio De Flora
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-03       Impact factor: 11.205

3.  REV1 is implicated in the development of carcinogen-induced lung cancer.

Authors:  Chad A Dumstorf; Suparna Mukhopadhyay; Elangovan Krishnan; Bodduluri Haribabu; W Glenn McGregor
Journal:  Mol Cancer Res       Date:  2009-01-27       Impact factor: 5.852

4.  Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer.

Authors:  Yian Wang; Weidong Wen; Yijun Yi; Zhongqiu Zhang; Ronald A Lubet; Ming You
Journal:  Cancer Prev Res (Phila)       Date:  2009-11-24

5.  Arsenic alters the function of the glucocorticoid receptor as a transcription factor.

Authors:  R C Kaltreider; A M Davis; J P Lariviere; J W Hamilton
Journal:  Environ Health Perspect       Date:  2001-03       Impact factor: 9.031

6.  Inhaled corticosteroids may prevent lung cancer in asthma patients.

Authors:  I-Jen Wang; Wen-Miin Liang; Trong-Neng Wu; Wilfried J J Karmaus; Jiin-Chyr Hsu
Journal:  Ann Thorac Med       Date:  2018 Jul-Sep       Impact factor: 2.219

7.  Polycyclic aromatic hydrocarbon-induced signaling events relevant to inflammation and tumorigenesis in lung cells are dependent on molecular structure.

Authors:  Ross S Osgood; Brad L Upham; Thomas Hill; Katherine L Helms; Kalpana Velmurugan; Pavel Babica; Alison K Bauer
Journal:  PLoS One       Date:  2013-06-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.